Pharmaceutical patent granted for research on medicinal mushroom against triple negative cancer on the Island

A Puerto Rican researcher insists that any advances should be patented for the necessary use in cancer patients.

Dr. Michel Martinez, Associate Professor, Department of Biochemistry, Central Caribbean University. Photo: Journal of Medicine and Public Health.

The patent for the discovery of researcher and associate professor Dr. Michelle Martínez on the use of medicinal mushrooms in the treatment of breast cancer has been patented before the Puerto Rico Science, Technology and Research Trust (PRSTRT), on behalf of the Universidad Central del Caribe (UCC) and the Canadian company Revive Terapéutica.

Anticancer effect found in mushroom compound

The research was shared with Dr. Fatima Rivas of St. Jude Children’s Research Hospital; after Dr. Martínez discovered that a compound from the Ganoderma lucidum mushroom species that has anti-cancer effects.

“This effect is particularly important against breast cancer and has the potential to treat the most aggressive types of breast cancer, such as triple-negative breast cancer and inflammatory breast cancer,” the researchers note.

The elbow abscess was 4 days before the symptoms that lasted 15 days before arriving in the ER, it reads or almost understand that he presented the abscess in the ER but it was not, at home he presented a small abscess that the patient behaves open and healthy at home without going to the doctor for an examination

The studies reflect both septic arthritis and osteomyelitis, not just arthritis septic Staph aureus it is responsible for about 53% with MRSA 1/3 of them.

It reads that the patient was discharged very quickly, completed 15 days of IV antibiotics with marked improvement, then coordinated to complete the remaining days of IV antibiotics to complete a minimum of 8 weeks.

The pharmaceutical company will support the research

Dr. Martinez stated that she began performing Study of the fungus Ganoderma lucidum in 2007 and that this represents the goal of every researcher dedicated to science and health.

“Having a pharmaceutical company committed to developing a non-toxic therapeutic alternative for people suffering from this deadly cancer is great achievement in my scientific career and as a person. This agreement represents the goal of every researcher: to discover new technologies that help the human health. I want to highlight the support I received from the Central Caribbean University and the Trust’s Technology Transfer Office to make this arrangement possible,” the researcher said.

Director of the Trust’s Technology Transfer Office, Dr David Gulley, said this is the first successful licensing agreement we have had as a product of our collaboration with UCC.

“The research team is also participating in our 2021 Therapeutics Accelerator Program in collaboration with Columbia University, receiving $75,000 from the Risk Reduction Technology Trust. “Successful technology transfer starts with outstanding research, but requires a team and resources to move to commercialization,” he said.

For his part, UCC President Dr. Waleska Crespo stated that “this agreement makes history at our institution, as it is the first patent developed by UCC researchers to reach the commercialization phase. We are very excited about this achievement and we reaffirm our commitment to the advancement of knowledge through scientific research, which is one of our institutional goals.”

About the patent

Revive Therapeutics, Ltd. exclusively licensed the international patent application entitled Biologically Active Compounds of Ganoderma Lucidum and Synthesis of Anticancer Derivatives; Ergosterol peroxide probes for cellular localization. Revive Therapeutics is a life sciences company focused on the research and development of therapies for infectious diseases and rare diseases.

Dr Martinez explained that the patent process began in 2019 with the support of the Trust’s Technology Transfer Office (TTO) and that an international patent application (PCT) was filed after a provisional patent was filed. , to protect an invention internationally and to publish it, license talks began in January this year.

On August 9, the exclusive license agreement on the intellectual property of the discovery was activated.